PF-05214030

• Description:

  PF-05214030 is a TRPV4 antagonist (IC50: 4 and 27nM for hTRPV4 and rTRPV4 respectively) . PF-05214030 reverses the reduction in bladder capacity caused by intravesical infusion of a TRPV4 agonist[1][2].

• UNSPSC:

  12352005

• Target:

  TRP Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/pf-05214030.html

• Purity:

  99.81

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  N#CC1=CC=C(C=C1F)OCC2(CN(S(=O)(C3=CC=C(C=C3Cl)Cl)=O)C2)O

• Molecular Formula:

  C17H13Cl2FN2O4S

• Molecular Weight:

  431.27

• References & Citations:

  [1]Jiang Y, et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022 Mar 24;15 (1) :34.|[2]Sarah Skerratt, et al. The Discovery and Optimisation of a Highly Selective Series of TRPV4 Antagonists.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  TRPV4

• CAS Number:

  [1669444-50-1]